Who makes BIBX 245 CL- fasted?

BIBX 245 CL- fasted is developed by Boehringer Ingelheim.

What development phase is BIBX 245 CL- fasted in?

BIBX 245 CL- fasted is in Phase 1.

Last reviewed 2026-04-20 · How we verify

BIBX 245 CL- fasted

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BIBX 245 CL- fasted
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BIBX 245 CL- fasted CI brief — competitive landscape report
BIBX 245 CL- fasted updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI